DakoCytomation announces potential sale of its microbiology activities
Advertisement
DakoCytomation, a world leader in cancer diagnostics, has decided to investigate the possibilities of selling its microbiology activities in order to sharpen its focus on cell-based cancer diagnostics.
"We see this as a strategic move to create a more focused business in DakoCytomation. Our microbiology activities are profitable and show increasing growth but are outside our core business strategy. We believe that this business will have even greater growth potential under new ownership. We expect both businesses to benefit from this move," says Patrik Dahlén, acting CEO of DakoCytomation.
The microbiology activities are a well-run and specialized part of DakoCytomation focusing on products for clinical use. The microbiology products are used for diagnosis and management of e.g. sexually transmitted diseases, respiratory diseases, Lyme disease, viral gastroenteritis and dyspepsia.
The microbiology business has annual sales of around DKK 100 million, sales growth of 10-15% and a staff of 70-80 professional sales people, researchers, manufacturing staff and administrative personnel based in our own facilities in Ely, United Kingdom.
Customers are clinical laboratories around the world. Business relationships with customers will not be affected by the work on the sale of these activities.
Other news from the department business & finance
These products might interest you
